Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call
Biote Corp BTMD
$2.25
▲ +1.35%
(+$0.03)
📅 Earnings This Week
Open
$2.28
Prev Close
$2.22
Day Range
$2.22 – $2.29
52W Range
$1.27 – $4.55
Market Cap
$84.56M
P/E (TTM)
5.42
Beta
1.65
EPS (TTM)
$0.44
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-03-02 |
| Shares Out. | 37,580,000 |
| Website | haymakeracquisition.com/ ↗ |
| Phone | 19724869346 |
| Employees | 223 |
| Revenue | $44.9M |
| Gross Profit | $31.0M |
| Net Income | $2.7M |
| Free Cash Flow | $27.3M |
| Total Assets | $89.0M |
| Total Liabilities | $137.0M |
| Equity | -$48.0M |
About Biote Corp
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
Biote Corp is a publicly traded company under the ticker symbol BTMD on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-07-01)